View Older Stories View More Recent Stories

Dec 13, 2021 07:18PM Update on Novartis Agreement
Dec 5, 2021 06:47PM Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
Nov 23, 2021 06:09PM Operational Highlights and Financial Results for the Period Ended September 30, 2021
Nov 23, 2021 07:18AM Mesoblast Corporate Update and Financial Results Webcast
Nov 21, 2021 07:31PM Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
Nov 14, 2021 07:13PM Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
Oct 28, 2021 07:51PM Appendix 4C Quarterly Activity Report
Oct 18, 2021 08:00AM Remestemcel-L Improves Survival of Children With Biomarkers for Highest Mortality in Steroid Refractory Acute GVHD
Oct 6, 2021 08:38PM Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting
Aug 30, 2021 07:38PM Operational Highlights and Financial Results for the Year Ended June 30, 2021
Aug 30, 2021 08:00AM Mesoblast Corporate Update and Financial Results Webcast
Jul 29, 2021 08:06PM Appendix 4C Quarterly Activity Report
Jul 18, 2021 08:58PM Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
Jul 15, 2021 08:15PM Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
Jun 30, 2021 07:46PM Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
Jun 2, 2021 08:01PM Operational Highlights and Financial Results for the Period Ended March 31, 2021
Jun 2, 2021 06:01PM Mesoblast Corporate Update and Financial Results Webcast
May 25, 2021 07:00AM Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
Apr 29, 2021 08:47PM Appendix 4C Quarterly Activity Report
Apr 29, 2021 07:32PM Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial
Apr 29, 2021 07:08PM Mesoblast Corporate Update
Mar 30, 2021 07:54PM Mesoblast Operational Highlights and Upcoming Milestones
Mar 29, 2021 08:00AM Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board
Mar 8, 2021 08:03PM Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
Mar 2, 2021 07:00AM Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
Feb 17, 2021 06:00AM Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19 Published in Pediatrics
Feb 10, 2021 06:42PM Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chroni
Feb 10, 2021 05:35PM Mesoblast Corporate Update
Jan 28, 2021 07:04PM Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
Jan 11, 2021 05:10PM Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
Jan 10, 2021 11:25PM Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
Dec 17, 2020 10:06PM Mesoblast Webcast – Update on COVID-19 ARDS Trial
Dec 17, 2020 06:31PM Mesoblast Update on COVID-19 ARDS Trial
Dec 14, 2020 05:28PM Mesoblast (MESO) Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure
Dec 14, 2020 05:27PM Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure
Dec 14, 2020 04:55PM Mesoblast Corporate Update
Dec 7, 2020 06:00AM Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease
Dec 2, 2020 06:19AM Mesoblast (MESO) Granted FDA Fast Track Designation for Remestemcel-L in Treatment of ARDS Due to COVID-19
Dec 2, 2020 06:00AM FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19
Nov 19, 2020 05:36PM Operational and Financial Results for the Period Ended September 30, 2020
Nov 19, 2020 05:12PM Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L
Nov 19, 2020 04:19PM Mesoblast Corporate Update and Financial Results Webcast
Nov 11, 2020 06:00AM Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS
Oct 22, 2020 06:00AM Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn’s Disease and Ulcerative Colitis
Oct 13, 2020 06:00AM Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
Oct 1, 2020 07:25PM Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Sep 15, 2020 06:00AM Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L
Sep 4, 2020 06:00AM Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With Acute Respiratory Distress Syndrome
Sep 2, 2020 06:00AM Mesoblast Receives Ethics Approval to Treat COVID-19 Patients in Australia
Aug 26, 2020 06:53PM Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020
View More Recent Stories View Older Stories